Abstract library

2 results for "Reidy-Lagunes".
#1504 Design of a Phase 3, International, Prospective, Randomized, Double-Blind, Placebo (PBO) Controlled Study Assessing Efficacy and Safety of Lanreotide Autogel/Depot (LAN) 120 mg in Patients with Well-Differentiated, Advanced Typical and Atypical Lung NETs
Introduction: The international phase 3 CLARINET study showed that treatment with the somatostatin analog (SSA) lanreotide was associated with significantly prolonged PFS vs PBO in GEP-NETs, leading to a new indication approved in more than 35 countries. Like GEP-NETs, lung NETs express somatostatin receptors.
Conference: 13th Annual ENETS conference (2016)
Category: ...none of the above
Presenting Author: George Camba
Keywords: Lung NETs, lanreotide
#1790 Lanreotide Autogel/Depot (LAN) in Lung Neuroendocrine Tumours (NETs): The Randomized, Double-Blind, Placebo (PBO)-Controlled, International Phase 3 SPINET Study
Introduction: Treatment options for advanced lung NETs are limited. The phase 3 CLARINET study demonstrated antitumour efficacy of somatostatin analogue (SSA) LAN 120mg vs PBO for metastatic gastroenteropancreatic grade 1/2 (Ki-67<10%) NETs, but prospective data on SSAs in advanced lung NETs are lacking.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Diane Reidy-Lagunes
Keywords: Lung NETs, lanreotide
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.